Showing a significant improvement in durable response rates compared to a GM-CSF-treated control group,32 thus Talimogene laherparepvec is currently (02/2015) undergoing US Food and Drug Administration33 and European Medicines Agency34 approval as a monotherapeutic agent for metastatic melanoma. Here, CSF2 is linked to metastatic melanoma.